IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
Rhea-AI Summary
IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.
Principal Investigator Dr. Angela Traylor will lead the site. Enrollment is reported as over 70% complete, and the addition aims to expand geographic reach and patient access.
Positive
- Enrollment >70% complete in the Phase 2 CALMA trial
- New investigational site in Metairie, LA expands geographic reach
- Experienced PI Dr. Angela Traylor added to trial leadership
Negative
- None.
News Market Reaction – IGC
In the Apr 7 session, IGC gained 0.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Site added to CALMA | Positive | +2.2% | Added Visionary Investigators Network site as CALMA approached 70% enrollment. |
| Feb 17 | IP and trial progress | Positive | +0.0% | Secured North American composition protection for IGC-AD1 as CALMA neared 70% enrollment. |
| Feb 09 | CALMA expansion abroad | Positive | +1.2% | Expanded CALMA into Colombia, growing to 23 active sites and ~70% enrollment. |
| Feb 02 | 70% enrollment update | Positive | +1.5% | Reported reaching ~70% enrollment with ~23 sites and mid-2026 completion goal. |
| Jan 22 | New CALMA site NY | Positive | +7.3% | Added Integrative Clinical Trials in Brooklyn to strengthen CALMA execution and data quality. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial updates for CALMA have generally coincided with modestly positive to flat moves, with an average same-tag reaction of about 2.45% across five recent events.
Over recent months, IGC has repeatedly updated investors on the Phase 2 CALMA trial, adding sites in New York, Miami, and Colombia while reporting that enrollment reached roughly 70% of the plan. These clinical updates often coincided with modestly positive price reactions, including a 7.31% move on a January site addition. The current news continues that pattern of expanding the trial network and operational infrastructure, reinforcing the focus on completing enrollment ahead of database lock and topline results.
Key Terms
phase 2 medical
clinical trial medical
principal investigator technical
alzheimer's disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.
The site, located at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, is led by Principal Investigator Dr. Angela Traylor, an experienced neurologist and psychiatrist who has served as both Principal Investigator and Sub-Investigator across multiple neurology and mental-health clinical studies. She will be supported by a seasoned Clinical Trial Coordination team with extensive experience in patient engagement and clinical-operations management.
"We are pleased to welcome Tandem Clinical Research as a new clinical partner in the CALMA trial," said Ram Mukunda, CEO of IGC Pharma. "With enrollment now over
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire